Actively Recruiting
Personalized Blood Pressure Management Compared to Standard Care in Adults With Cardiogenic Shock
Led by CMC Ambroise Paré · Updated on 2026-09-29
406
Participants Needed
11
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate whether adjusting the mean arterial pressure MAP target based on central venous pressure CVP can improve organ function and survival in adults with cardiogenic shock, a serious condition where the heart cannot pump enough blood, leading to organ damage and high death rates. The study compares personalized MAP targets to the standard MAP target to see if individualizing blood pressure goals can better protect organs and improve outcomes. Participants receive blood pressure management in one of two ways either a personalized MAP target calculated as 65 mmHg plus the measured CVP range 65-75 mmHg plus CVP, not exceeding 90 mmHg, or a standard MAP target of 65-70 mmHg following current guidelines. CVP is measured through a central venous catheter. After 48 hours, the personalized MAP target may be lowered if tissue perfusion has improved. Throughout the study, participants are monitored for survival, organ function, and need for mechanical support over 7, 28, and 90 days. Researchers assess mortality, kidney failure, use of circulatory support and dialysis, as well as various clinical scores and complications like arrhythmias and bleeding. The primary outcome combines death, use of mechanical circulatory support, and severe kidney failure. The study is randomized and will last until July 2029.
CONDITIONS
Brief Title
Personalisation of Mean Arterial Pressure in Adult Patients With Cardiogenic Shock
Research Team
A
Armand MEKONTSO DESSAP, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here